Clinical trials: Chemotherapy-Related Toxicities
Anthracyclines-Induced Cardiotoxicity, Cardiotoxicity
Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity
Anthracyclines, such as doxorubicin, are effective anticancer agents but may cause dose-dependent cardiac injury, including early changes in left ventricular function and cardiac biomarkers.
- Trial name
- DAPA-AIC (NCT06888505)
- Testing
- Dapagliflozin (Forxiga)
- Where
- Iraq
- Volunteers
- 94 people
- Sponsor
- Hawler Medical University
Ovarian Cancer
Exercise Preconditioning in Ovarian Cancer
The purpose of this study is to determine if exercise preconditioning can mitigate the off target effects of chemotherapy treatment on measures of cardiovascular function, peripheral neuropathy, and quality of life.
- Trial name
- NCT05029154
- Testing
- High intensity interval exercise, Attention control
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Virginia
Cardiotoxicity Induced by Drug Therapy for Breast Cancer
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.
- Trial name
- START (NCT06214195)
- Testing
- Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Zhejiang Cancer Hospital
Toxicity Due to Chemotherapy, Cardiovascular Morbidity
Investigating Cardiovascular Adverse Events Related to Cancer Treatment
Cisplatin, anthracyclines, bleomycin and trastuzumab can cause severe cardiovascular or pulmonary toxicity. Why some patients are susceptible to extreme toxicity of cancer treatment is largely unknown.
- Conditions
- Toxicity Due to Chemotherapy, Cardiovascular Morbidity, Cancer, Treatment-Related
- Trial name
- InvestiCAT (NCT03199300)
- Testing
- Anthracyclines, Trastuzumab, Cisplatin
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
Breast Cancer Female
Caloric Restriction and Exercise for Protection From Anthracycline Toxic Effects
Doxorubicin and epirubicin are part of the class of chemotherapy agents called anthracyclines that are commonly used to treat breast cancer.
- Trial name
- CREATE (NCT03131024)
- Testing
- 50% caloric restriction, Aerobic exercise
- Where
- Canada
- Volunteers
- 58 people
- Sponsor
- University of Alberta
Cancer, Cancer-related Problem/Condition
Cancer and Aging Research Group (CARG) Chemotherapy Toxicity Risk Scores in Older Adults With Cancer in China
The goal of this observational study is to learn about the impact of chemotherapy-related toxicity on older cancer patients in China.
- Trial name
- NCT06717178
- Testing
- Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 360 people
- Sponsor
- RenJi Hospital
Breast Cancer, Breast Neoplasm
Evaluating an AI-Based Mobile Application for Chemotherapy Support in Breast Cancer Patients
The goal of this clinical trial is to learn if an Arabic-language mobile application that uses artificial intelligence (AI) can help women with breast cancer during chemotherapy.
- Conditions
- Breast Cancer, Breast Neoplasm, Chemotherapy-Related Toxicities, Medication Adherence
- Trial name
- AI-ChemoApp (NCT07273812)
- Testing
- AI-Based Mobile Application for Personalized Chemotherapy Support, Usual Care
- Where
- Iraq
- Volunteers
- 130 people
- Sponsor
- Dena h. Al-Tameemi
Breast Cancer, Cardiac Toxicity
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00436566
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Mayo Clinic
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003068
- Testing
- amifostine trihydrate, cyclophosphamide, mitoxantrone hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Arizona
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
RATIONALE: Keratinocyte growth factor may prevent symptoms of mucositis in patients receiving radiation therapy and chemotherapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004132
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes, Neutropenia
- Trial name
- NCT00003407
- Testing
- amifostine trihydrate, cytarabine, mitoxantrone hydrochloride
- Where
- 4 sites in United States
- Sponsor
- Rush University Medical Center
Immune-related Adverse Event, Chemotherapeutic Toxicity
Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma
The goal of the study is to learn about Safety and efficacy of preoperative adjuvant SOX regimen combined with nivolumab versus FLOT Regimen with nivolumab in HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma.
- Conditions
- Immune-related Adverse Event, Chemotherapeutic Toxicity, Gastric or Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT06440811
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- Xijing Hospital
Cardiotoxicity, Toxicity Due to Chemotherapy
Pilot Study of an NTproBNP Guided Strategy of Cardioprotection
Investigators will evaluate the safety and feasibility of a biomarker-guided cardioprotection strategy using NTproBNP, as compared to usual care, in breast cancer and lymphoma patients treated with anthracyclines.
- Conditions
- Cardiotoxicity, Toxicity Due to Chemotherapy, Breast Cancer, Lymphoma
- Trial name
- NTproBNP-Guide (NCT04737265)
- Testing
- Biomarker Guided Intervention
- Where
- 3 sites in United States
- Volunteers
- 108 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cardiac Toxicity, Sarcoma
Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003937
- Testing
- cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride
- Where
- 148 sites in United States, Australia and 4 more
- Volunteers
- 253 people
- Sponsor
- Children's Oncology Group
Lymphoma
Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- ManteauRiBVD (NCT00740415)
- Testing
- rituximab, bortezomib, dexamethasone
- Where
- France
- Volunteers
- 39 people
- Sponsor
- French Innovative Leukemia Organisation
Cardiotoxicity, Chemotherapeutic Toxicity
Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients
In cancer patients, the increase of troponin I soon after chemotherapy is a strong predictor of left ventricular dysfunction and poor cardiologic outcome.
- Trial name
- NCT00292526
- Testing
- Enalapril
- Where
- Italy
- Volunteers
- 114 people
- Sponsor
- European Institute of Oncology